BeiGene (NASDAQ:BGNE) Reaches New 52-Week Low at $131.50

Shares of BeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) hit a new 52-week low during trading on Wednesday . The company traded as low as $131.50 and last traded at $131.83, with a volume of 48835 shares changing hands. The stock had previously closed at $134.05.

Analysts Set New Price Targets

BGNE has been the topic of a number of recent research reports. Bank of America reduced their target price on shares of BeiGene from $179.30 to $164.30 and set a "neutral" rating on the stock in a research report on Monday, April 8th. Guggenheim cut their price target on BeiGene from $350.00 to $345.00 and set a "buy" rating on the stock in a research note on Tuesday, February 27th. JPMorgan Chase & Co. raised their price objective on BeiGene from $184.00 to $186.00 and gave the company an "overweight" rating in a research report on Tuesday, March 19th. Finally, Sanford C. Bernstein dropped their target price on BeiGene from $196.00 to $161.00 and set a "market perform" rating on the stock in a report on Wednesday, March 27th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, BeiGene presently has an average rating of "Moderate Buy" and an average price target of $251.70.

BeiGene Stock Performance

The business has a fifty day moving average price of $155.97 and a 200-day moving average price of $169.12. The stock has a market capitalization of $12.61 billion, a P/E ratio of -15.51 and a beta of 0.61. The company has a quick ratio of 2.09, a current ratio of 2.32 and a debt-to-equity ratio of 0.06.

BeiGene (NASDAQ:BGNE - Get Free Report) last posted its earnings results on Monday, February 26th. The company reported ($3.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.61) by $0.08. BeiGene had a negative net margin of 35.86% and a negative return on equity of 23.12%. The business had revenue of $634.40 million for the quarter, compared to analysts' expectations of $632.52 million. During the same quarter in the prior year, the business earned ($4.29) EPS. The business's revenue for the quarter was up 66.9% compared to the same quarter last year. On average, sell-side analysts expect that BeiGene, Ltd. will post -8.87 EPS for the current year.

Insider Activity at BeiGene

In other BeiGene news, CEO John Oyler sold 37,668 shares of BeiGene stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $164.02, for a total value of $6,178,305.36. Following the completion of the sale, the chief executive officer now owns 12,332 shares of the company's stock, valued at approximately $2,022,694.64. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CFO Julia Aijun Wang sold 397 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $167.08, for a total value of $66,330.76. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO John Oyler sold 37,668 shares of the business's stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $164.02, for a total transaction of $6,178,305.36. Following the sale, the chief executive officer now owns 12,332 shares of the company's stock, valued at $2,022,694.64. The disclosure for this sale can be found here. Insiders have sold a total of 64,781 shares of company stock worth $10,222,381 over the last quarter. Company insiders own 7.40% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. raised its stake in shares of BeiGene by 175.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company's stock worth $38,658,000 after buying an additional 136,458 shares during the period. Virtu Financial LLC lifted its holdings in BeiGene by 94.2% during the fourth quarter. Virtu Financial LLC now owns 5,319 shares of the company's stock valued at $959,000 after purchasing an additional 2,580 shares in the last quarter. Exome Asset Management LLC purchased a new position in BeiGene during the fourth quarter valued at approximately $2,309,000. Virtus ETF Advisers LLC boosted its position in shares of BeiGene by 19.2% in the fourth quarter. Virtus ETF Advisers LLC now owns 1,739 shares of the company's stock worth $314,000 after purchasing an additional 280 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of BeiGene by 9.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,908,189 shares of the company's stock worth $344,162,000 after purchasing an additional 158,624 shares in the last quarter. 48.55% of the stock is currently owned by institutional investors.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.